Changeflow GovPing Pharma & Drug Safety Solid Form Composition for Use in Treatment of ...
Routine Rule Added Final

Solid Form Composition for Use in Treatment of Extraoesophageal Symptoms of Gastric Reflux

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3752202A1 filed by Drugs Minerals and Generics Italia S.R.L. for a solid dosage form composition intended for treating extraoesophageal symptoms of gastric reflux. The application, filed with inventor Luigi Mercuri, designates multiple EU member states including DE, FR, GB, IT, ES, NL, and 24 others. This publication establishes a priority date for the claimed pharmaceutical composition.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published patent application EP3752202A1 for a solid form pharmaceutical composition designed for treating extraoesophageal symptoms associated with gastric reflux. The application claims a composition under IPC classifications A61K 47/36, A61K 47/44, A61K 9/16, and A61K 9/20.

For pharmaceutical manufacturers and drug developers, this publication establishes a priority date for potential claims in the solid dosage formulation space for extraoesophageal reflux treatments. Competitors developing similar formulations should conduct freedom-to-operate analyses and monitor the prosecution of this application through the EPO examination process.

Archived snapshot

Apr 19, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPOSITION IN SOLID FORM FOR USE IN THE TREATMENT OF EXTRAOESOPHAGEAL SYMPTOMS OF GASTRIC REFLUX

Publication EP3752202A1 Kind: A1 Apr 08, 2026

Applicants

Drugs Minerals and Generics Italia S.R.L.
In Forma Abbreviata D.M.G. Italia S.R.L.

Inventors

MERCURI, Luigi

IPC Classifications

A61K 47/36 20060101AFI20190823BHEP A61K 47/44 20170101ALI20190823BHEP A61K 9/16 20060101ALI20190823BHEP A61K 9/20 20060101ALI20190823BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3752202A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Pharmaceutical composition
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!